-
2023-508571-37-00
4
2022-04-29
Geographic atrophy (GA) secondary to Age-related Macular Degeneration
-
2024-511560-93-00
5
2022-03-29
Schizophrenia
-
2024-513096-41-00
4
2022-03-24
sickle cell disease
-
2022-502542-28-00
4
2021-12-06
Sickle Cell Disease
-
2023-507431-37-00
5
2021-07-23
relapsing multiple sclerosis (RMS)
-
2023-507317-10-00
5
2021-05-10
Locally advanced, unresectable, or metastatic non small cell lung canc
-
2023-508485-15-00
5
2021-04-22
Subjects with documented STEMI, presenting with persistent ischemic ch
-
2024-514344-82-00
5
2021-02-18
patients with acute respiratory failure from undetermined etiology
-
2024-512456-38-00
4
2021-02-04
locally advanced squamous cell carcinoma
-
2023-506724-85-00
5
2020-11-19
Migraine
-
2023-506253-38-00
5
2020-11-09
Migraine
-
2024-514471-18-00
5
2020-05-13
Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Mar
-
2024-516407-16-00
5
2020-04-10
Patients admitted to the ICU proven or suspected infection as the main
-
2024-512537-33-00
5
2019-11-28
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
-
2024-515308-38-00
5
2019-09-21
Adults patients with isolated acute urticaria presenting to the emerge
-
2024-516201-23-00
4
2019-08-26
Lung Cancer, NSCLC
-
2024-511885-35-00
5
2019-07-03
macular telangiectasia type 1
-
2024-512352-38-00
4
2019-03-28
Hepatitis B, Chronic
-
2023-507312-13-00
5
2018-11-15
Multiple Myeloma
-
2024-519336-16-00
10
2018-10-31
Relapsed or Refractory Angioimmunoblastic T cell Lymphoma
-
2024-516098-62-00
5
2018-01-11
External Genital Warts (EGW)
-
2022-502526-41-00
4
2016-03-15
Non-Muscle Invasive Bladder Cancer (NMIBC)
-
2024-517856-36-00
5
2015-03-09
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
-
2023-504034-22-00
5
2014-12-18
Chronic Lymphocytic Leukemia (CLL)